Testing gefurulimab in children with generalized myasthenia gravis
Part of Brain & nervous system, Cancer, Immune system & allergy clinical trials.
This study tests a new drug called gefurulimab in children and teens with generalized myasthenia gravis (a disease that causes muscle weakness). It looks at how safe and effective the drug is, and how it works in the body.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 6 and 17 years old (ages 12 to 17 in the US).
- You must have a diagnosis of generalized myasthenia gravis (muscle weakness beyond just the eyes).
- You must have a positive blood test for AChR antibodies.
- You must be vaccinated against meningitis (groups A, B, C, W, Y) within the last 3 years, or be willing to get the vaccine or take antibiotics.
- You cannot have had thymus gland surgery in the past 12 months or have an untreated thymus tumor.
- You cannot be pregnant, breastfeeding, or planning to become pregnant during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests if an investigational drug called inebilizumab is safe and helpful for children with generalized myasthenia gravis (gMG). It is for children ages 2 to 17 who have certain antibodies or typical symptoms of gMG and are already on stable treatment.
This study gives an injectable medicine called zilucoplan to children who were part of an earlier trial and could benefit from more treatment. It aims to see if zilucoplan is safe and helpful for young patients with generalized myasthenia gravis.
This trial studies how efgartigimod (given through a vein) behaves in children and whether it is safe and effective for generalized myasthenia gravis. It is designed for children who have not done well enough with standard treatments like steroids or other immune medicines.
This trial tests multiple treatment combinations for people with myasthenia gravis (MG), a condition that causes muscle weakness. It aims to find safer and more effective options by comparing different therapies.
This study tests an investigational drug called efgartigimod for children and teens with generalized myasthenia gravis. It may help those who haven't responded well enough to standard treatments.
This trial tests whether ravulizumab, a medication that blocks part of the immune system, can improve muscle weakness and fatigue in people with generalized myasthenia gravis (gMG). The study focuses on Chinese adults who have moderate-to-severe MG symptoms despite current treatments.
Hear when a new Generalized Myasthenia Gravis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.